CN210472631U - Controlled release capsule for stomach medication - Google Patents
Controlled release capsule for stomach medication Download PDFInfo
- Publication number
- CN210472631U CN210472631U CN201921142309.9U CN201921142309U CN210472631U CN 210472631 U CN210472631 U CN 210472631U CN 201921142309 U CN201921142309 U CN 201921142309U CN 210472631 U CN210472631 U CN 210472631U
- Authority
- CN
- China
- Prior art keywords
- capsule
- release
- controlled release
- controlled
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 78
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 238000013270 controlled release Methods 0.000 title claims abstract description 54
- 229940079593 drug Drugs 0.000 title claims abstract description 50
- 210000002784 stomach Anatomy 0.000 title abstract description 7
- 241000596504 Tamarindus Species 0.000 claims description 20
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 20
- 150000004676 glycans Chemical class 0.000 claims description 20
- 229920001282 polysaccharide Polymers 0.000 claims description 20
- 239000005017 polysaccharide Substances 0.000 claims description 20
- 230000002496 gastric effect Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 239000011257 shell material Substances 0.000 description 20
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model discloses a controlled release capsule for stomach medication, which is divided into a quick release part and a controlled release part, wherein the quick release part and the controlled release part are arranged up and down to form a capsule whole; the quick release portion includes a second capsule shell and a quick release medicament, the quick release medicament being located inside the second capsule shell; the controlled release portion includes a first capsule shell and a controlled release drug, the controlled release drug being located inside the first capsule shell; the first capsule shell and the second capsule shell are matched and butted up and down to form the whole capsule. The quick release part of the controlled release capsule can quickly release the medicine for quickly relieving the state of illness; the release control part can control the release speed of the medicine, so that the medicine can be slowly absorbed by a subsequent human body, and the bioavailability of the medicine is improved.
Description
Technical Field
The utility model belongs to the technical field of medical supplies, relate to medical capsule, concretely relates to controlled release capsule for stomach medication.
Background
Some stomach diseases are easy to cause sudden onset, and the drug is required to be released rapidly to relieve the disease condition, and after the disease condition is initially relieved, the drug is required to be released slowly and continuously. However, the existing stomach medicine capsules are all fast disintegrated and have small diameter, once the capsule shells are broken, the absorption speed of human bodies to medicine particles is far faster than that of tablets.
When the medicine is released in a certain amount, the state of illness is initially relieved, and people hope that the medicine can be slowly absorbed by human bodies, so that the medicine needs to be quickly released in an early stage and slowly released in a later stage. In the prior art, the existing capsules on the market have single functions, and the functions of different controlled release medicines are not considered.
SUMMERY OF THE UTILITY MODEL
In view of the above problems in the prior art, the present invention provides a controlled release capsule for gastric administration, which is divided into a fast release part and a controlled release part, wherein the fast release part can fast release the drug to quickly relieve the state of an illness; the release control part can control the release speed of the medicine, so that the medicine can be slowly absorbed by a subsequent human body, and the bioavailability of the medicine is improved.
Therefore, the utility model adopts the following technical scheme:
a controlled release capsule for stomach administration comprises a rapid release part and a controlled release part, which are arranged up and down to form a capsule; the quick release portion includes a second capsule shell and a quick release medicament, the quick release medicament being located inside the second capsule shell; the controlled release portion includes a first capsule shell and a controlled release drug, the controlled release drug being located inside the first capsule shell; the first capsule shell and the second capsule shell are matched and butted up and down to form the whole capsule.
Preferably, the controlled release drug is a tablet mainly composed of tamarind seed polysaccharide and drug, and the release speed of the controlled release drug is determined by the ratio of tamarind seed polysaccharide.
Preferably, the tablet further comprises water-soluble starch or dextrin for improving the release rate of the controlled release drug.
Preferably, the first capsule shell is made of tamarind polysaccharide or a mixed material containing tamarind polysaccharide more than 40%.
Preferably, the second capsule shell is made of gelatin or a hollow capsule material conforming to the national pharmacopoeia.
Preferably, the fast-release drug is a drug microparticle.
Compared with the prior art, the beneficial effects of the utility model are that:
(1) by processing the capsule shell by two different materials and modes, the medicine particles in the quick release structure are quickly absorbed by a human body along with the dissolution of the capsule shell material after the capsule is taken, and the other part of the medicine is wrapped by the tamarind polysaccharide and can be absorbed by the human body after the medicine permeates through the gel layer or the gel is eroded, so that the absorption of the part of the medicine by the human body is slow.
(2) The capsule has the advantages of rapid drug release speed in the first period and slow drug release speed in the later period, and can rapidly relieve the state of an illness, control the drug concentration in human blood, reduce the side effect of overhigh drug concentration on human body, and control the drug concentration of human body in a reasonable range in a long time.
(3) Simple structure, convenient use and improved bioavailability.
Drawings
Fig. 1 is a schematic structural composition diagram of a controlled release capsule for gastric administration provided by the present invention.
Fig. 2 is a graph comparing the release rate of the controlled release capsule provided in the examples of the present invention with that of a commercially available capsule.
Description of reference numerals: 1. a first capsule shell; 2. controlled release of the drug; 3. the drug is released rapidly; 4. a second capsule shell.
Detailed Description
The present invention will be described in detail with reference to the accompanying drawings and specific embodiments, which are only used for explaining the present invention, but not for limiting the present invention.
As shown in figure 1, the utility model discloses a controlled release capsule for stomach medication, which is divided into a rapid release part and a controlled release part, wherein the rapid release part and the controlled release part are arranged up and down to form a capsule whole; the quick release portion comprises a second capsule shell 4 and a quick release medicament 3, the quick release medicament 3 being located inside the second capsule shell 4; the controlled-release part comprises a first capsule shell 1 and a controlled-release drug 2, the controlled-release drug 2 being located inside the first capsule shell 1; the first capsule shell 1 and the second capsule shell 4 are matched up and down and butted to form a whole capsule.
Specifically, the controlled release drug 2 is a tablet mainly composed of tamarind seed polysaccharide and a drug, and the release rate of the controlled release drug 2 is determined by the ratio of tamarind seed polysaccharide.
Specifically, the tablet further comprises water-soluble starch or dextrin for improving the release rate of the controlled release drug 2. The slow release speed of tamarind polysaccharide is improved by reducing the ratio of tamarind polysaccharide.
Specifically, the first capsule shell 1 is made of tamarind seed polysaccharide or a mixed material containing tamarind seed polysaccharide more than 40%.
Specifically, the second capsule shell 4 is made of gelatin or hollow capsule materials conforming to the national pharmacopoeia.
Specifically, the quick-release drug 3 is a drug microparticle.
Examples
To examine the effect of the controlled release capsules, the following experiments were designed: 12 rabbits (Shanghai laboratory animal center) weighing about 1.8-2.2kg each, were fasted for 24h before the experiment and fed with water only. Cimetidine (anti-peptic ulcer drug) was administered at a dose of 20mg/kg, one group was a control group, and each was orally administered with a common commercially available gelatin capsule (cimetidine capsule); the other group was experimental group, each oral tamarind seed polysaccharide controlled release capsule (tamarind seed polysaccharide tablet containing 50% of tablet and fine particle drug containing 50%). At preset time intervals, blood is taken from the ear edge vein of the rabbit, centrifugal separation is carried out, and high performance liquid chromatography is carried out for analysis, so that the controlled release effect is obvious. The results of the experiment are shown in table 1.
TABLE 1 comparison of the results
| Dosage forms | Tmax | Cmax | AUC(0-8h)(ug h ml-1) | MRT(h) |
| Controlled release capsules | 6.2±0.3 | 1.0±0.3 | 3.2±0.8 | 7.5±0.1 |
| Commercially available capsules | 2.4±0.6 | 1.5±0.2 | 4.0±0.3 | 4.9±0.4 |
In Table 1, TmaxRepresents the time at which the maximum blood concentration is reached in units of h; cmaxRepresents the maximum blood concentration after one administration in mg/L; AUC represents the area under the plasma drug concentration-time curve, represents the total absorption amount after one-time administration, and reflects the absorption degree of the drug; MRT represents the mean residence time of the drug molecule in vivo.
In addition, tamarind seed polysaccharide controlled release capsule containing 0.2 g of acetaminophen (wherein tamarind seed polysaccharide tablet contains 50% of acetaminophen, and the content of particulate drug is 50%) and common commercially available gelatin capsule were measured for release rate at different times according to the method described for acetaminophen capsule in Chinese pharmacopoeia 2005 edition. The results are shown in FIG. 2.
From fig. 2 it can be found that: the release rate of the common commercial gelatin capsule reaches 92.7 percent within one hour, while the release rate of the tamarind seed polysaccharide controlled release capsule is less than 50 percent within 1 hour, the release rate is 71.6 percent within 12 hours, and the release rate reaches 90 percent within 24 hours. The controlled release capsule has the advantages of fast drug release speed in the first period and slow drug release speed in the later period, and can rapidly relieve the state of an illness, control the drug concentration in the blood of a human body and reduce the side effect of overhigh drug concentration on the human body.
The above description is only for the preferred embodiment of the present invention and should not be taken as limiting the invention, and any modifications, equivalent replacements, and improvements made within the spirit and principle scope of the present invention should be included within the protection scope of the present invention.
Claims (6)
1. A controlled release capsule for gastric administration is characterized in that: the capsule is divided into a quick release part and a controlled release part, and the quick release part and the controlled release part are arranged up and down to form a capsule whole; the quick release part comprises a second capsule shell (4) and a quick release medicine (3), and the quick release medicine (3) is positioned inside the second capsule shell (4); the controlled release portion comprises a first capsule shell (1) and a controlled release drug (2), the controlled release drug (2) being located inside the first capsule shell (1); the first capsule shell (1) and the second capsule shell (4) are matched and butted up and down to form the whole capsule.
2. The controlled-release capsule for gastric administration of claim 1, wherein: the controlled release drug (2) is a tablet mainly composed of tamarind seed polysaccharide and a drug, and the release speed of the controlled release drug (2) is determined by the ratio of the tamarind seed polysaccharide.
3. The controlled-release capsule for gastric administration of claim 2, wherein: the tablet also comprises water-soluble starch or dextrin for improving the release speed of the controlled release drug (2).
4. The controlled-release capsule for gastric administration of claim 1, wherein: the first capsule shell (1) is made of tamarind seed polysaccharide or a mixed material with tamarind seed polysaccharide content exceeding 40%.
5. The controlled-release capsule for gastric administration of claim 1, wherein: the second capsule shell (4) is made of gelatin or hollow capsule materials conforming to the national pharmacopoeia.
6. The controlled release capsule for gastric administration of any one of claims 1 to 5, wherein: the quick release medicament (3) is a medicament particle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201921142309.9U CN210472631U (en) | 2019-07-19 | 2019-07-19 | Controlled release capsule for stomach medication |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201921142309.9U CN210472631U (en) | 2019-07-19 | 2019-07-19 | Controlled release capsule for stomach medication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN210472631U true CN210472631U (en) | 2020-05-08 |
Family
ID=70531757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201921142309.9U Active CN210472631U (en) | 2019-07-19 | 2019-07-19 | Controlled release capsule for stomach medication |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN210472631U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200948A (en) * | 2019-07-19 | 2019-09-06 | 曹郁 | A kind of stomach medication controlled release capsule |
-
2019
- 2019-07-19 CN CN201921142309.9U patent/CN210472631U/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200948A (en) * | 2019-07-19 | 2019-09-06 | 曹郁 | A kind of stomach medication controlled release capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1053339C (en) | Controlled release morphine preparation | |
| JPS5959633A (en) | Manufacture of release controlled composite unit composition | |
| US20170028007A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
| CN210472631U (en) | Controlled release capsule for stomach medication | |
| CN103520129B (en) | Montelukast sodium pulse release preparation | |
| CN112675131A (en) | Oroxylin pharmaceutical composition and application thereof in preparation of liver cancer drugs | |
| CN101874817B (en) | Brucea javanica oil enteric-coated microcapsule and preparation method | |
| CN103585357B (en) | Callicarpa nudiflora slow and its preparation method and application | |
| CN112569190B (en) | Oral administration preparation of pulsatilla chinensis saponin B4 and preparation method thereof | |
| CN112089699B (en) | Loratadine sustained-release tablet and preparation process thereof | |
| CN105726503A (en) | Levofloxacin hydrochloride tablet | |
| CN105412039A (en) | Frovatriptan succinate controlled-release tablet and preparation method thereof | |
| CN105748427B (en) | A kind of Topiroxostat enteric coatel tablets and preparation method thereof | |
| CN113018271A (en) | Tandospirone pharmaceutical composition and preparation method and application thereof | |
| CN1872107B (en) | Chinese and Western compound preparations of alpha receptor blocking pharmacon, preparation method, and application | |
| CN110200948A (en) | A kind of stomach medication controlled release capsule | |
| CN108785273B (en) | Entecavir capsule pharmaceutical composition and preparation method thereof | |
| CN104337783B (en) | A kind of capecitabine tablet and preparation method thereof | |
| CN115531350B (en) | Azilsartan capsule and preparation method thereof | |
| CN102114003B (en) | Sustained-release pellet of hydroxysafflor yellow A as well as preparation method and applications thereof | |
| US20100034887A1 (en) | Bursting Pellets | |
| CN114432257B (en) | Bluprofen sustained-release tablet and preparation method thereof | |
| CN113209037B (en) | Oxiracetam osmotic pump controlled release tablet and application thereof | |
| WO2024041662A1 (en) | Posaconazole solid dispersion and preparation method therefor | |
| CN101766608B (en) | Compound pseudoephedrine hydrochloride slow release preparation and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200717 Address after: 430070 Huada Garden B3-2-102, Lushi South Road, Hongshan District, Wuhan City, Hubei Province Co-patentee after: Shandong Dixing Biotechnology Co., Ltd Patentee after: Cao Yu Address before: 430070 Huada Garden B3-2-102, Lushi South Road, Hongshan District, Wuhan City, Hubei Province Patentee before: Cao Yu |